As shown in Figure 3, CT26 tumour-bearing mice were treated with suboptimal doses of OATD-02, epacadostat or anti-PD-L1 antibody, which led to a partial inhibition of the tumour growth (TGI: 33% for OATD-02, p = 0.0042 vs. controls; 41% for epacadostat, p = 0.035 vs. controls; 33% for anti-PD-L1 antibody, p = 0.0462 vs. controls). Here, CD274 is linked to neoplasm.